Clinical Trial

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Study acronym: FORAGER-2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.
Protocol Amendment History 1 change
notable Trial sites expanded: 284 -> 287 locations 2026-07-08
Trial Details
NCT Number NCT07218380
Lead Sponsor Eli Lilly and Company
Conditions Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Enrollment 450 participants
Start Date 2025-12-12
Primary Completion 2029-10 (estimated)
Study Completion 2033-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-13